See clearly. Treat optimally.
Better care for more people
Use it. Trust it. Love it.
IVUS has the potential to change treatment plans and improve patient outcomes. But don’t just take our word for it. Many clinical studies have shown the importance of using IVUS to help you visualize the best path forward – before, during and after treatment.
Real-world results to improve patient outcomes (1-4)
79%
change of treatment plants [1]
Prospective RCT of 150 patients undergoing fempop interventions, showed that reference vessel diameters measured by IVUS were larger than measured by angiography alone in 86% of cases and smaller in 10.7% of cases. Lesion length was also longer with IVUS, than with angiography in 56.7% of cases.
27%
reduction in major adverse limb events [3]
Data from the largest ever real-world clinical analysis of over 700,000 peripheral arterial and peripheral venous patients on lower extremity peripheral intervention for IVUS, demonstrate a 27% reduction in risk for major adverse limb events including acute limb ischemia or major amputation
Why vessel preparation matters?
Prepare the vessel for better outcomes [5-13] and fewer complications [6-20]. Atherectomy and scoring solutions, designed to enable effective therapy delivery.
38% lower amputation rates with laser [5]
Laser plus DCB reduces the amputation rate by 38%, from 46% with DCB alone to 8% with Laser and DCB
< 2% dissections with AngioSculpt Balloon [6-13]
Angiosculpt Scoring Ballon flow limiting dissections will be reduced from up to 38% to maximum 2% compared to PTA alone
< 1% distal embolization with Phoenix [14-20]
Phoenix atherectomy has less than 1% distal embolization without any filter use in more than 1000 patients over 7 studies
Preparation is everything
Atherectomy and scoring solutions, designed to enable effective therapy delivery.
Want to learn more?
Learn with the Experts – Join our upcoming webinars with key opinion leaders and top users on how to optimise PAD outcomes with intravascular imaging and vessel preparation.
1/3
Footnotes
- Allan RB et al. The Impact of Intravascular Ultrasound on Femoropopliteal Artery Endovascular Interventions: A Randomized Controlled Trial. JACC Cardiovasc Interv. 2022 Mar 14;15(5):536-546. doi: 10.1016/j.jcin.2022.01.001. PMID: 35272779
- Ko YG, Lee SJ, Ahn CM, Lee SH, Lee YJ, Kim BK, Hong MK, Jang Y, Kim TH, Park HW, Jang JY, Lee JH, Park JH, Kim SH, Im E, Park SH, Choi D; IVUS-DCB investigators. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial. Eur Heart J. 2024 Aug 16;45(31):2839-2847. doi: 10.1093/eurheartj/ehae372. PMID: 38966936
- Divakaran S, et al. Temporal Trends, Practice Variation, and Associated Outcomes With IVUS Use During Peripheral Arterial Intervention. JACC Cardiovasc Interv. 2022 Oct 24;15(20):2080-2090. doi: 10.1016/j.jcin.2022.07.050. PMID: 36265940; PMCID: PMC9758975.
- Soga Y, et al. Clinical impact of intravascular ultrasound-guided balloon angioplasty in patients with chronic limb threatening ischemia for isolated infrapopliteal lesion. Catheter Cardiovasc Interv. 2021 Feb 15;97(3):E376-E384. doi: 10.1002/ccd.29347. Epub 2020 Oct 21. PMID: 33085185.
- Gandini R, Del Giudice C, Merolla S, Morosetti D, Simonetti G. Treatment of Chronic SFA In-Stent Occlusion With Combined Laser Atherectomy and Drug-Eluting Balloon Angioplasty in Patients With Critical Limb Ischemia: A Single-Center, Prospective, Randomized Study. Journal of Endovascular Therapy. 2013;20(6):805-814. doi:10.1583/13-4308MR.1
- Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3(3): 267-76.
- Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropoplitealrevascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014; 7(1): 10-9.
- Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12- month results from the IN.PACT SFA randomized trial. Circulation 2015; 131(5): 495-502.
- Gary Ansel, IN.PACT Global Update and Sub-analysis: TASC C-D lesions. Oral presentation. LINC 2015, Leipzig, Germany. Jan 27-30, 2015.
- Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358(7): 689-99.
- Micari A, Cioppa A, VadalaG, et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv 2013; 6(3): 282-9.
- Bosiers M, Deloose K et al. Use of the AngioSculptscoring balloon for infrapopliteal lesions in patients with critical limb ischemia: 1-year outcome. Vascular. 2009;17:29-35
- Scheinert D, Peeters P, Bosiers M, et al. Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease. Catheter Cardiovasc Interv. 2007;70:1034-1039.
- Davis T, Ramaiah V, Niazi K, Martin Gissler H, Crabtree T. Safety and effectiveness of the Phoenix Mechanical Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. 2017 Dec;25(6):563-575. doi: 10.1177/1708538117712383. Epub 2017 Sep 27. PMID: 28950783; PMCID: PMC5714160.
- Gandini R, Pratesi G, Merolla S, Scaggiante J, Chegai F. A Single-Center Experience With Phoenix Mechanical Atherectomy System in Patients With Moderate to Heavily Calcified Femoropopliteal Lesions. Cardiovasc Revasc Med. 2020 May;21(5):676-681. doi: 10.1016/j.carrev.2019.08.019. Epub 2019 Aug 23. PMID: 31488361.
- Giusca S, Lichtenberg M, Schueler M, Heinrich U, Eisenbach C, Andrassy M, Korosoglou G. Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing Phoenix Mechanical Atherectomy. Heart Vessels. 2021 Mar;36(3):366-375. doi: 10.1007/s00380-020-01695-w. Epub 2020 Sep 10. Erratum in: Heart Vessels. 2022 Apr;37(4):711. PMID: 32914347.
- Janas A, Milewski K, Buszman P, Kolarczyk-Haczyk A, Trendel W, Pruski M, Wojakowski W, Buszman P, Kiesz RS. Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease. Postepy Kardiol Interwencyjnej. 2020 Mar;16(1):76-81. doi: 10.5114/aic.2020.93914. Epub 2020 Apr 3. PMID: 32368239; PMCID: PMC7189125.
- Montero-Baker M, Phoenix 500: Final Results from the Phoenix Registry, oral presentation, LINC 2020
- Giusca S, Hagstotz S, Lichtenberg M, Heinrich U, Eisenbach C, Andrassy M, Korosoglou G. Phoenix Mechanical Atherectomy for patients with peripheral artery disease. EuroIntervention. 2022 Aug 5;18(5):e432-e442. doi: 10.4244/EIJ-D-21-01070. PMID: 35389346.
- G. Korosoglou, Phoenix atherectomy in 500 patients with PAD, oral presentation, LINC 2023.
- Kumarasamy A, Gombert A, Krabbe J, Ruprecht O, Jacobs MJ, Krabbe H. Assessment of Feasibility and Patency of below the Knee Atherectomy Using the 1.5 mm Phoenix Catheter-A Retrospective Study. Medicina (Kaunas). 2022 Nov 3;58(11):1594. doi: 10.3390/medicina58111594. PMID: 36363551; PMCID: PMC9699591
- *Patients affected by critical limb ischemia (CLI) and superficial femoral artery (SFA) chronic stent occlusion
Disclaimer
Always read the label and follow the directions for use. Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.
Products subject to country availability. Please contact your local sales representative. ©2025 Koniklijke Philips N.V. All rights reserved. Trademarks are the property of Koninklijke Philips N.V. or their respective owners. Philips reserves the right to change product specifications without prior notification.
Better care for more people